{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:38:23Z","timestamp":1787600303561,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13058-016-0721-5","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T15:57:41Z","timestamp":1467043061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18"],"prefix":"10.1186","volume":"18","author":[{"given":"Richard S.","family":"Finn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Crown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor M.","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindranath","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindy T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sashi","family":"Nadanaciva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Huang","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"issue":"11","key":"721_CR1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"721_CR2","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"721_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"5","key":"721_CR4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb\u2009+\u2009advanced breast cancer: phase ii activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21(5):995\u20131001.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"721_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"21","key":"721_CR6","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21(21):4760\u20136.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"721_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000366466","volume":"9","author":"C Fontanella","year":"2014","unstructured":"Fontanella C, Bolzonello S, Lederer B, Aprile G. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care (Basel). 2014;9(4):239\u201345.","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"721_CR8","first-page":"131","volume":"34","author":"V Bhatt","year":"2004","unstructured":"Bhatt V, Saleem A. Review: Drug-induced neutropenia\u2014pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004;34(2):131\u20137.","journal-title":"Ann Clin Lab Sci"},{"issue":"10","key":"721_CR9","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258\u201366.","journal-title":"Cancer"},{"issue":"23","key":"721_CR10","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555\u201363.","journal-title":"Cancer"},{"issue":"9","key":"721_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/11592980-000000000-00000","volume":"30","author":"SL Michels","year":"2012","unstructured":"Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH. Costs associated with febrile neutropenia in the US. Pharmacoeconomics. 2012;30(9):809\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"32","key":"721_CR12","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1200\/JCO.2015.61.5831","volume":"33","author":"MJ Ellis","year":"2015","unstructured":"Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiowka M, Hewson N, et al. Fulvestrant 500\u00a0mg versus anastrozole 1\u00a0mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33(32):3781\u20137.","journal-title":"J Clin Oncol"},{"issue":"30","key":"721_CR13","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","volume":"26","author":"RJ Paridaens","year":"2008","unstructured":"Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883\u201390.","journal-title":"J Clin Oncol"},{"issue":"5","key":"721_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1056\/NEJMoa1201622","volume":"367","author":"RS Mehta","year":"2012","unstructured":"Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"721_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10549-012-2192-4","volume":"136","author":"JF Robertson","year":"2012","unstructured":"Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Fulvestrant 500\u00a0mg versus anastrozole 1\u00a0mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat. 2012;136(2):503\u201311.","journal-title":"Breast Cancer Res Treat"},{"key":"721_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-319-16366-6_3","volume":"862","author":"A Hurria","year":"2015","unstructured":"Hurria A, Muss H. Special issues in older women with breast cancer. Adv Exp Med Biol. 2015;862:23\u201337.","journal-title":"Adv Exp Med Biol."},{"issue":"3","key":"721_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.critrevonc.2014.07.003","volume":"92","author":"S Guiu","year":"2014","unstructured":"Guiu S, Wolfer A, Jacot W, Fumoleau P, Romieu G, Bonnetain F, et al. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Crit Rev Oncol Hematol. 2014;92(3):235\u201357.","journal-title":"Crit Rev Oncol Hematol"},{"key":"721_CR18","unstructured":"US Prescribing Information for Ibrance\u00ae. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207103s000lbl.pdf . Accessed 24 October 2015."}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-016-0721-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0721-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T07:49:04Z","timestamp":1656748144000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-016-0721-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1186\/s13058-016-0721-5","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,28]]},"article-number":"67"}}